DA
SUPN icon

Denali Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Denali Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-38
Closed -$1K – 364
2021
Q1 		$1K Hold
38
– – ﹤0.01% 363
2020
Q4 		$1K Buy
+38
New +$818 ﹤0.01% 383

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Denali Advisors's SUPN Position: Q2 2021 in Review

Denali Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q2 2021, closing a stake of 38 shares — an estimated $1K sold.

Denali Advisors first reported a position in SUPN in Q4 2020 and held it in 2 quarters. The position peaked at $1K in Q1 2021. 226 funds tracked by Wall St. Rank hold SUPN as of Q2 2021.

  • Denali Advisors reported no remaining Supernus Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Denali Advisors sold 38 Supernus Pharmaceuticals shares in Q2 2021, an estimated $1K.
  • Denali Advisors first reported a position in Supernus Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Denali Advisors's Supernus Pharmaceuticals position peaked at $1K in Q1 2021.
  • 226 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2021.

Based on Denali Advisors's 13F filing for Q2 2021, filed 20 Aug 2021.